Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;227(4):152240.
doi: 10.1016/j.imbio.2022.152240. Epub 2022 Jul 6.

The significance of antiglobulin (Coombs) test reactivity in patients with COVID-19

Wael Hafez  1 , Mohamad Azzam Ziade  2 , Arun Arya  2 , Husam Saleh  2 , Ahmed Abdelrahman  3
Affiliations

The significance of antiglobulin (Coombs) test reactivity in patients with COVID-19

Wael Hafez et al. Immunobiology. 2022 Jul.

Abstract

Previous case reports have described patients with COVID-19-associated autoimmune hemolytic anemia (AIHA), and cold agglutinin disease (CAD) which is characterized by a positive direct antiglobulin (DAT) or "Coombs" test, yet the mechanism is not well understood. To investigate the significance of Coombs test reactivity among COVID-19 patients, we conducted a retrospective study on hospitalized COVID-19 patients treated at NMC Royal Hospital between 15 April and 30 May 2020. There were 27 (20%) patients in the Coombs-positive group and 108 (80%) in the Coombs-negative group. The cold agglutinin titer was examined in 22 patients due to symptoms suggestive of cold agglutinin disease, and all tested negative. We demonstrated a significant association with reactive Coombs test results in univariate analysis through clinical findings such as ICU admission rate, the severity of COVID-19, and several laboratory findings such as CRP, D-dimer, and hemoglobin levels lactate dehydrogenase, and RDW-CV. However, only hemoglobin levels and disease severity had a statistically significant association in multivariate analysis. A possible explanation of COVID-19-associated positive Coombs is cytokine storm-induced hyperinflammation, complement system activation, alterations of RBCs, binding of SARS-CoV-2 proteins to hemoglobin or its metabolites, and autoantibody production. Coombs-positive patients were tested for hemolysis using indirect bilirubin, consumed haptoglobin, and/or peripheral smear that ruled out any evidence of hemolysis. Understanding this etiology sheds new light on RBC involvement as a pathophysiological target for SARS-CoV-2 by interfering with their function; consequently, therapies capable of restoring RBC function, such as erythrocytapheresis, could be repurposed for the treatment of worsening severe and critical COVID-19.

Keywords: Anemia; Antiglobulin (Coombs) test; Erythrocytapheresis; Hemoglobinopathy; Hemolysis; Red blood cell.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Algassim A.A., Elghazaly A.A., Alnahdi A.S., Mohammed-Rahim O.M., Alanazi A.G., Aldhuwayhi N.A., Alanazi M.M., Almutairi M.F., Aldeailej I.M., Kamli N.A., Aljurf M.D. Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection. Ann. Hematol. 2021;100(1):37–43. doi: 10.1007/s00277-020-04256-3. - DOI - PMC - PubMed
    1. Angileri, F., Légaré, S., Marino Gammazza, A., Conway de Macario, E., Macario, A. J. L., & Cappello, F. (2020). Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID-19? In British Journal of Haematology (Vol. 190, Issue 2, pp. e92–e93). Blackwell Publishing Ltd. 10.1111/bjh.16883. - PMC - PubMed
    1. Baines A.C., Brodsky R.A. Complementopathies. Blood Rev. 2017;31(4):213–223. doi: 10.1016/j.blre.2017.02.003. - DOI - PMC - PubMed
    1. Bastard P., Rosen L.B., Zhang Q., Michailidis E., Hoffmann H.-H., Zhang Y.u., Dorgham K., Philippot Q., Rosain J., Béziat V., Manry J., Shaw E., Haljasmägi L., Peterson P., Lorenzo L., Bizien L., Trouillet-Assant S., Dobbs K., de Jesus A.A., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science (New York, N.Y.) 2020;370(6515) doi: 10.1126/science.abd4585. - DOI - PMC - PubMed
    1. Berentsen S. Cold agglutinin disease. Hematology. 2016;2016(1):226–231. doi: 10.1182/asheducation-2016.1.226. - DOI - PMC - PubMed